Glaxo Malaria Shot Protects for 18 Months in Africa Study
This article is for subscribers only.
GlaxoSmithKline Plc’s experimental malaria vaccine cut infections over 18 months in a late-stage study, moving researchers a step closer to making the first protective shot against the disease available as early as 2015.
The RTS,S candidate reduced infections by 46 percent in infants ages 5 months to 17 months, and by 27 percent for 6-to-12-week-old babies in the follow-up period after the first vaccination, the PATH Malaria Vaccine Initiative, which is developing the protection with Glaxo, said in a statement today. The trial involved more than 15,000 children in Africa.